Categories Earnings, Health Care

Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot

— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.

— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.

Earnings Update by AlphaStreet

— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.

— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.

— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Earnings: KB Home (KBH) Q2 2024 profit rises despite lower revenues

Homebuilder KB Home (NYSE: KBH) on Tuesday announced financial results for the second quarter of 2024, reporting an increase in net income. Revenues were down 3%. The company’s net income

What to expect when General Mills (GIS) reports its fourth quarter 2024 earnings results

Shares of General Mills, Inc. (NYSE: GIS) stayed green on Tuesday. The stock has dropped 5% over the past one month. The processed foods company is scheduled to report its

Lennar Corporation (LEN) Earnings: 2Q24 Key Numbers

Lennar Corporation (NYSE: LEN) reported total revenues of $8.8 billion for the second quarter of 2024, up 9% year-over-year. Net earnings attributable to Lennar were $954 million, or $3.45 per share, compared to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top